Want to join the conversation?
$AGN CEO Brent Saunders stated that in 4Q15, it enhanced category leadership through the Anterios acquisition, a licensing agreement with Mimetogen and research collaboration with Rugen Therapeutics. The company has made progress with Teva on the planned divestiture of its Global Generics business.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?